Evaluation of the Mutational Profile Pretreatment and Posttreatment
A total of 79 mutations were detected in 30 patients (76.9%) at the time of first biopsy (range, 1–6; median 2). All 12 patients in the C-Olaparib group carried mutations at the time of first biopsy. Likewise, more than half of the patients in the D-Olaparib (7/12 patients; 58.3%) and Olaparib only (8/10 patients; 80%) group had mutations prior to treatment administration with most of them being identified in the 